Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238421 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR | |
| SCHEMBL12238423 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR | |
| SCHEMBL12239045 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR | |
| SCHEMBL12239034 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR | |
| SCHEMBL12238422 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR | |
| SCHEMBL2520512 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR | |
| SCHEMBL12238424 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR | |
| SCHEMBL1897862 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR | |
| SCHEMBL12239044 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR | |
| SCHEMBL12239048 | 1.00 | GABRR1 (0.35) | GABRR1LMNACYP1A2CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251289-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | CSIR (ZA) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251289-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | DUT, BAD, TYMS | GABRR1 2885/4885LMNA 3575/4885CYP1A2 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.